Proactive Investors - Run By Investors For Investors

Leaf Resources continues positive progress in phase 3 IDS design study in The Netherlands

The company is converting biomass to functional industrial sugars to substitute petrochemicals used in manufacturing.
Leaf Resources continues positive progress in phase 3 IDS design study in The Netherlands
Leaf Resources is one of the word’s leading companies in converting plant biomass into industrial sugars

Leaf Resources Limited (ASX:LER) has received positive progress on its latest integrated demonstration study (IDS) in Delft, The Netherlands from the month of January.

The company partnered with Bioprocess Pilot Facility (BPF) to undertake a series of integrated demonstration studies that incorporated the necessary engineering and hardware components in the pilot-scale testing.

This testing is critical in the overall validation program for Leaf’s proprietary Glycell technology and is an essential input to the design and financing requirements for the company’s proposed biorefinery project in Malaysia.

“On track” collecting valuable data

Leaf’s CEO Alex Baker said: “We are currently on track and capturing valuable data and knowledge on the Glycell process that will be fed in the FEL 3 engineering program conducted by TechnipFMC.

“We are impressed with the combined efforts of BPF and the Leaf technical team and look forward to continuing with this important validation of the process."

Leaf Resources is one of the world's leading companies in converting plant biomass into industrial sugars.

Its proprietary process for converting biomass-to-functional industrial sugars enables a myriad of downstream technologies for the production of renewable chemicals that will substitute petrochemicals used in manufacturing today.

Performing as designed

The IDS restarted in January with performance qualification continuing as the equipment and processes were optimised in an integrated fashion.

During the month, 170 run hours were performed with fully integrated campaign runs successfully operated for extended periods.

The equipment sets with each unit operation are performing as designed and the data is being produced in a timely fashion allowing parameter testing to be carried out in real time.

Study to continue 

The IDS will continue through the first quarter of 2019 and the company will provide regular updates on its progress.

- Jessica Cummins



View full LER profile View Profile

Leaf Resources Ltd Timeline

October 27 2016

Related Articles

September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use